Martin Schönlein
@mschoenlein.bsky.social
Clinician Scientist/ Postdoc @obenaufa.bsky.social at the Research Institute of Molecular Pathology (IMP) in Vienna. Hematology/ Oncology Residency @University Medical Center Hamburg-Eppendorf. Interested in #Cancer #Metastasis #TherapeuticVulnerabilities
Reposted by Martin Schönlein
Extremely happy to receive the 2024 Denise Barlow Award for my PhD work. Grateful to my mentor @obenaufa.bsky.social and the entire Obenauf lab, all collaborators, and the award committee for this recognition!
🎉 Congrats to @aelewaut.bsky.social for winning the 2024 #DenisePBarlowAward! 🎖️
She carried out her PhD thesis in @obenaufa.bsky.social's lab (@impvienna.bsky.social), work published in @nature.com.
📄 Paper: rdcu.be/eQv1f
➡️ About the award: bit.ly/3iFbafP
She carried out her PhD thesis in @obenaufa.bsky.social's lab (@impvienna.bsky.social), work published in @nature.com.
📄 Paper: rdcu.be/eQv1f
➡️ About the award: bit.ly/3iFbafP
November 20, 2025 at 10:39 PM
Extremely happy to receive the 2024 Denise Barlow Award for my PhD work. Grateful to my mentor @obenaufa.bsky.social and the entire Obenauf lab, all collaborators, and the award committee for this recognition!
Reposted by Martin Schönlein
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y
October 18, 2025 at 8:00 AM
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y
Reposted by Martin Schönlein
🔥Trio Fatale: Neutrophils, NETs and Necrosis
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
September 9, 2025 at 3:20 PM
🔥Trio Fatale: Neutrophils, NETs and Necrosis
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
👉 authors.elsevier.com/a/1lk-k3qNrU...
We summarized for @cp-immunity.bsky.social
"Neutrophils drive vascular occlusion, tumour necrosis and metastasis" published in @nature.com by @megeblad.bsky.social @adrover.bsky.social rdcu.be/eFdau
Congrats!
Reposted by Martin Schönlein
After this year's Crazy 8 Summit, we are more motivated than ever to cure the incurable.
We want to thank all of the childhood cancer researchers who gathered at this year's Crazy 8 Summit. Without your dedication and collaboration, we could not make this much of an impact for kids with cancer.
We want to thank all of the childhood cancer researchers who gathered at this year's Crazy 8 Summit. Without your dedication and collaboration, we could not make this much of an impact for kids with cancer.
March 24, 2025 at 5:57 PM
After this year's Crazy 8 Summit, we are more motivated than ever to cure the incurable.
We want to thank all of the childhood cancer researchers who gathered at this year's Crazy 8 Summit. Without your dedication and collaboration, we could not make this much of an impact for kids with cancer.
We want to thank all of the childhood cancer researchers who gathered at this year's Crazy 8 Summit. Without your dedication and collaboration, we could not make this much of an impact for kids with cancer.